All In Biotech

Drug Trial Radar · NCT06643481

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2, Randomized, Double-blind, Placebo-controlled Parallel Group Study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) Over 40 Weeks Followed by an Open Label Extension (ASTRALS)

Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

251

Actual

Start

Oct 17, 2024

Primary completion

Jun 23, 2026

Study completion Jul 10, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • VHB937Biological

    VHB937 solution for infusion

  • PlaceboOther

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The composite of PAV-free survival and change in ALSFRS-R. Analysis method: Combined Assessment of Function and Survival (CAFS)Time frame: Baseline to DB Week 40

Locations

74 sites in 17 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Loma Linda University Health

    Loma Linda, California

  • Keck Medical Center USC

    Los Angeles, California

  • UC San Francisco Medical Center

    San Francisco, California

  • University of Miami

    Miami, Florida

  • Orlando Health Clinical Trials

    Orlando, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • University Of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Lange Neurology PC

    New York, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Atrium Health

    Charlotte, North Carolina

  • Duke University Health System

    Durham, North Carolina

  • Univ of Cincinnati Medical Center

    Cincinnati, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Temple University

    Philadelphia, Pennsylvania

  • AMR Knoxville

    Knoxville, Tennessee

  • Austin Neuromuscular Center

    Austin, Texas

  • Nerve and Muscle Center of Texas

    Houston, Texas

  • University of Washington Medical Center

    Seattle, Washington

  • Novartis Investigative Site

    Southport, Australia

  • Novartis Investigative Site

    North Ryde, New South Wales, Australia

  • Novartis Investigative Site

    Herston, Queensland, Australia

  • Novartis Investigative Site

    Caulfield South, Victoria, Australia

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site

    Calgary, Alberta, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Aalborg, Denmark

  • Novartis Investigative Site

    Kobenhavn N V, Denmark

  • Novartis Investigative Site

    Bron, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Nice, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Tours, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Lübeck, Germany

Showing 40 of 74 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.